Gene therapies push AAV vector production

Our Technical Lead, Kai Touw, has been interviewed by BioPharm International to discuss the challenges of AAV vector production for gene therapy.
Batavia Biosciences - Favicon

Several virus types have been studied for use as viral vectors in gene therapy, including adenovirus, lentivirus, retrovirus, and adeno-associated virus (AAV). All platforms have their own advantages over one of the others. The recent successes with AAV and lentivirus give these vectors a boost in development. In combination with the fact that they are well studied, might make them the frontrunner for some therapeutic applications. Our Technical Lead, Kai Touw, has been interviewed by BioPharm International to discuss the potential and challenges of viral vector production for gene therapy.

Link to full article.

Related

New Test for Rapid and Low-cost Quality Control for Polio Vaccines

Batavia Biosciences has developed a qPCR method that can specifically detect mutations that can accumulate in poliovirus strains during vaccine production. The test demonstrates a sensitivity level highly comparable to current best practices. The novel test has been accepted for publication in the international, peer-reviewed prestigious Vaccine journal.

Viral Vector Production Guide

Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression